KPAX002-1: Alzheimer's Disease

Phase 2 ready. We are ready to implement a proof-of-concept, biomarker based trial to demonstrate the safety and efficacy of KPAX002 as a treatment for cognitive dysfunction in Alzheimer's disease.

KPAX002-2: Parkinson's Disease

Phase 2 ready. We are ready to implement a proof-of-concept, biomarker based trial to demonstrate the safety and efficacy of KPAX002 as a means of halting the progression of motor and non-motor symptoms in Parkinson's disease.

KPAX002-3:  Amyotrophic Lateral Sclerosis (ALS) 

Phase 2 ready. We are ready to implement a proof-of-concept trial to demonstrate the safety and efficacy of KPAX002 as a treatment to slow the progression of Amyotrophic lateral sclerosis (ALS).

Questions regarding partnering opportunities can be directed to K-PAX Pharmaceuticals' Director of Operations, Anne Lahaderne at: This email address is being protected from spambots. You need JavaScript enabled to view it. or by calling (415) 381-7655.